Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Eiger Biopharmaceuticals (EIGRQ) has provided an announcement.
Eiger BioPharmaceuticals, Inc. and its subsidiaries, which filed for Chapter 11 bankruptcy in April 2024, have warned investors not to base investment decisions on their recently filed Monthly Operating Reports. These reports, required by the bankruptcy court and not prepared under GAAP, may be unreliable and subject to change. Shareholders are urged to exercise extreme caution when trading the company’s securities due to the high risk and potential for complete loss depending on the bankruptcy outcome.
For a thorough assessment of EIGRQ stock, go to TipRanks’ Stock Analysis page.